{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:49:54Z","timestamp":1761407394132,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.sleep.2023.04.019","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:48:08Z","timestamp":1682650088000},"page":"202-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy"],"prefix":"10.1016","volume":"107","author":[{"given":"Steven T.","family":"Szabo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth C.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S.","family":"Koblan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.sleep.2023.04.019_bib1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sleep.2023.04.019_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","article-title":"Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy","volume":"43","author":"Szabo","year":"2019","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.sleep.2023.04.019_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"issue":"36","key":"10.1016\/j.sleep.2023.04.019_bib4","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1523\/JNEUROSCI.2630-12.2012","article-title":"Narcolepsy: neural mechanisms of sleepiness and cataplexy","volume":"32","author":"Burgess","year":"2012","journal-title":"J\u00a0Neurosci"},{"issue":"11","key":"10.1016\/j.sleep.2023.04.019_bib5","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S1388-2457(03)00203-7","article-title":"Clinical aspects and pathophysiology of narcolepsy","volume":"114","author":"Dauvilliers","year":"2003","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.sleep.2023.04.019_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.sleep.2019.09.001","article-title":"Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications","volume":"68","author":"Thorpy","year":"2020","journal-title":"Sleep Med"},{"issue":"6","key":"10.1016\/j.sleep.2023.04.019_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0269881115573807","article-title":"GHB for cataplexy: possible mode of action","volume":"29","author":"Szabadi","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.sleep.2023.04.019_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fphar.2017.00987","article-title":"The case for TAAR1 as a modulator of central nervous system function","volume":"8","author":"Rutigliano","year":"2017","journal-title":"Front Pharmacol"},{"issue":"16","key":"10.1016\/j.sleep.2023.04.019_bib9","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1073\/pnas.151105198","article-title":"Trace amines: identification of a family of mammalian G protein-coupled receptors","volume":"98","author":"Borowsky","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.sleep.2023.04.019_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bcp.2009.05.031","article-title":"Trace amine-associated receptor 1 as a monoaminergic modulator in brain","volume":"78","author":"Xie","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.sleep.2023.04.019_bib11","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1212\/WNL.0000000000013128","article-title":"Metabolomics signature of patients with narcolepsy","volume":"98","author":"Dauvilliers","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2023.04.019_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419875622","article-title":"Recent advances in treatment for narcolepsy","volume":"12","author":"Barateau","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.sleep.2023.04.019_bib13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41380-019-0469-2","article-title":"Amphetamines signal through intracellular TAAR1 receptors coupled to G\u03b1(13) and G\u03b1(S) in discrete subcellular domains","volume":"26","author":"Underhill","year":"2021","journal-title":"Mol Psychiatr"},{"issue":"20","key":"10.1016\/j.sleep.2023.04.019_bib14","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.sleep.2023.04.019_bib15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41386-019-0386-8","article-title":"Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in cynomolgus macaques","volume":"44","author":"Goonawardena","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.sleep.2023.04.019_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.biopsych.2016.10.012","article-title":"Trace amine-associated receptor 1 agonists as narcolepsy therapeutics","volume":"82","author":"Black","year":"2017","journal-title":"Biol Psychiatr"},{"issue":"9","key":"10.1016\/j.sleep.2023.04.019_bib17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.5665\/sleep.2972","article-title":"Influence of inhibitory serotonergic inputs to orexin\/hypocretin neurons on the diurnal rhythm of sleep and wakefulness","volume":"36","author":"Tabuchi","year":"2013","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2023.04.019_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145700001772","article-title":"Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors","volume":"3","author":"Szabo","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"10.1016\/j.sleep.2023.04.019_bib19","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00213-016-4282-1","article-title":"Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT","volume":"233","author":"Mori","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.sleep.2023.04.019_bib20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-3565(25)24542-6","article-title":"Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy","volume":"272","author":"Nishino","year":"1995","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"2","key":"10.1016\/j.sleep.2023.04.019_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0893-133X(95)00159-B","article-title":"Ipsapirone, a 5-HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls","volume":"15","author":"Gillin","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.sleep.2023.04.019_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.sleep.2009.05.004","article-title":"The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy","volume":"10","author":"Black","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2023.04.019_bib23","volume":"3","author":"Kornum","year":"2017","journal-title":"Narcolepsy. Nat Rev Dis Primers."},{"issue":"7","key":"10.1016\/j.sleep.2023.04.019_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2023.04.019_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D(2) receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.sleep.2023.04.019_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-021-01331-9","article-title":"Effect of TAAR1\/5-HT(1A) agonist SEP-363856 on REM sleep in humans","volume":"11","author":"Hopkins","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"10","key":"10.1016\/j.sleep.2023.04.019_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/psp4.12692","article-title":"Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia","volume":"10","author":"Galluppi","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.sleep.2023.04.019_bib28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/sleep\/9.4.519","article-title":"Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness","volume":"9","author":"Carskadon","year":"1986","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.sleep.2023.04.019_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/sleep\/22.2.171","article-title":"Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness","volume":"22","author":"Jewett","year":"1999","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleep.2023.04.019_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/sleep\/15.4.376","article-title":"Reliability and factor analysis of the Epworth sleepiness scale","volume":"15","author":"Johns","year":"1992","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.sleep.2023.04.019_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jsr.12363","article-title":"Sleep-stage sequencing of sleep-onset REM periods in MSLT predicts treatment response in patients with narcolepsy","volume":"25","author":"Drakatos","year":"2016","journal-title":"J\u00a0Sleep Res"},{"issue":"5","key":"10.1016\/j.sleep.2023.04.019_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz296","article-title":"A\u00a0circuit perspective on narcolepsy","volume":"43","author":"Adamantidis","year":"2020","journal-title":"Sleep"},{"issue":"Pt 5","key":"10.1016\/j.sleep.2023.04.019_bib33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awt069","article-title":"Electroencephalogram paroxysmal \u03b8 characterizes cataplexy in mice and children","volume":"136","author":"Vassalli","year":"2013","journal-title":"Brain"},{"issue":"9560","key":"10.1016\/j.sleep.2023.04.019_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","volume":"369","author":"Dauvilliers","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.sleep.2023.04.019_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S1461145710000076","article-title":"Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons","volume":"14","author":"Guiard","year":"2011","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945723001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945723001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:45:08Z","timestamp":1761407108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945723001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"alternative-id":["S1389945723001491"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2023.04.019","relation":{},"ISSN":["1389-9457"],"issn-type":[{"type":"print","value":"1389-9457"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2023.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}